Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Expert Discusses Docetaxel Versus Abiraterone in Hormone-Sensitive Prostate Cancer

February 14th 2018

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

Dr. Koontz Discusses LHRH in High-Risk Prostate Cancer

February 14th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses a phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Sequencing Questions Remain in Prostate Cancer Paradigm

February 13th 2018

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.

Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix, Leuprolide in Prostate Cancer

February 11th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

Dr. Gulley Discusses a Phase II Study of Olaparib and Durvalumab in mCRPC

February 10th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service, at the National Cancer Institute, discusses a phase II study of olaparib (Lynparza) and durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer (mCRPC) in an unselected patient population, presented at the 2018 Genitourinary Cancers Symposium.

SM-88 Delays Recurrence for Nonmetastatic Prostate Cancer

February 9th 2018

Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.

Olaparib/Durvalumab Combo Shows Promise in mCRPC

February 9th 2018

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Dr. Plimack Discusses Trials Investigating Apalutamide, Enzalutamide in M0 CRPC

February 9th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).

FDA Approves Abiraterone for High-Risk Prostate Cancer

February 8th 2018

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

February 7th 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Docetaxel Adds to QALY in Advanced Prostate Disease

February 6th 2018

The addition of docetaxel (Taxotere) to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy, contributing to lower overall costs in the nonmetastatic setting.

Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer

February 6th 2018

Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III SPARTAN trial.

Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC

February 6th 2018

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wise on AR-Directed Therapy for Prostate Cancer

February 3rd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses advancements with androgen receptor (AR)-directed therapy for patients with prostate cancer.

Dr. Taneja Discusses Multiparametric MRI in Prostate Cancer

February 3rd 2018

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

Update Sustains OS Benefit of Chemohormonal Therapy in High-Volume Prostate Cancer

February 2nd 2018

Adding docetaxel to androgen-deprivation therapy improved overall survival by nearly 17 months in men with high-volume metastatic hormone-sensitive prostate cancer.

Dr. Mason on Treatment Decisions Following 10-Year PROTECT Data in Prostate Cancer

February 1st 2018

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy for patients with prostate cancer following the 10-year PROTECT study data.

Expert Highlights Significance of MRI-Guided Prostate Biopsies

February 1st 2018

Samir Taneja, MD, discusses his research on MRI-guided prostate biopsies and other modalities in development.

Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer

February 1st 2018

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

Dr. Oh on Abiraterone Versus Docetaxel in Prostate Cancer

January 31st 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.